Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Operating Leases (2019 - 2025)

Cumberland Pharmaceuticals' Operating Leases history spans 7 years, with the latest figure at $4.5 million for Q4 2025.

  • For Q4 2025, Operating Leases fell 9.47% year-over-year to $4.5 million; the TTM value through Dec 2025 reached $4.5 million, down 9.47%, while the annual FY2025 figure was $4.5 million, 9.47% down from the prior year.
  • Operating Leases for Q4 2025 was $4.5 million at Cumberland Pharmaceuticals, down from $5.0 million in the prior quarter.
  • Across five years, Operating Leases topped out at $5.8 million in Q2 2023 and bottomed at $22712.0 in Q1 2022.
  • The 5-year median for Operating Leases is $4.8 million (2022), against an average of $3.9 million.
  • The largest annual shift saw Operating Leases tumbled 98.76% in 2022 before it surged 20627.01% in 2023.
  • A 5-year view of Operating Leases shows it stood at $90016.0 in 2021, then soared by 5187.07% to $4.8 million in 2022, then grew by 13.23% to $5.4 million in 2023, then decreased by 8.33% to $4.9 million in 2024, then decreased by 9.47% to $4.5 million in 2025.
  • Per Business Quant, the three most recent readings for CPIX's Operating Leases are $4.5 million (Q4 2025), $5.0 million (Q3 2025), and $4.7 million (Q2 2025).